Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biofrontera Inc. filings document a Nasdaq-listed dermatology biopharmaceutical company focused on photodynamic therapy. The company’s Form 8-K reports cover financial results, preliminary revenue updates, clinical disclosures for Ameluz PDT programs, patent-related proceedings, and Nasdaq continued-listing compliance notices. Its registered securities include common stock under BFRI and warrants under BFRIW.
Proxy materials describe board elections, stockholder voting matters, equity incentive plan approvals, auditor ratification, and governance procedures. The filing record also reflects disclosure controls around non-GAAP financial measures, Regulation FD announcements, risk-related litigation and patent matters, and capital-structure items such as warrants and preferred stock purchase rights.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.
Hoffman Beth J. reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Beth J. Hoffman reported receiving an award of 20,000 employee stock options on March 4, 2026. The options were granted at a reported price of $0.0000 per share. They vest in twelve equal monthly installments beginning on April 4, 2026. After this grant, she holds 20,000 options directly.
Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.
Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.
Biofrontera Inc. reports a significant development in its patent dispute with Sun Pharmaceutical Industries. On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun’s U.S. Patent No. 11,697,028 unpatentable.
Sun may still request rehearing, seek review by the Director of the U.S. Patent and Trademark Office, or appeal to the U.S. Court of Appeals for the Federal Circuit, so the outcome is not yet final. The company notes that the impact of this decision on ongoing proceedings in the U.S. District Court for the District of Massachusetts and the International Trade Commission cannot be determined at this time.
Rosalind Master Fund L.P. and related parties report beneficial ownership of approximately 9.9% of Biofrontera Inc. common shares. The stake is reported on a passive basis and is calculated using 11,648,323 common shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. may be deemed to beneficially own 1,140,764 common shares, with additional 15,048,017 shares issuable from preferred shares and convertible debt that are subject to a 9.99% ownership blocker and therefore not currently exercisable. Rosalind Advisors, Inc. acts as investment adviser, and portfolio managers Steven Salamon and Gilad Aharon may be deemed beneficial owners but disclaim beneficial ownership.
Biofrontera Inc. reported positive, statistically significant Phase 3 results for Ameluz® photodynamic therapy (PDT) to treat mild to moderate actinic keratoses on the extremities, neck, and trunk using its RhodoLED® platform.
Ameluz® PDT achieved complete clearance in 45.6% of patients in the Full Analysis Set, versus 16.7% with vehicle PDT (p < 0.0003), and 53.2% versus 22.2% in the Per Protocol Set (p < 0.001). Lesion clearance reached 73.1% in the Full Analysis Set and 80.3% in the Per Protocol Set. Investigators rated cosmetic outcomes as good or very good in 75.2% of patients, and 86.3% indicated they would choose PDT again. Based on these data, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for a potential label expansion beyond the face and scalp.
Biofrontera Inc. received an updated ownership disclosure from AIGH-related entities and Orin Hirschman. The reporting persons state beneficial ownership of 915,210 shares of common stock, representing 7.9% of the class. These securities are held with sole voting and dispositive power.
The filing notes an additional 14,642,510 common shares are issuable upon conversion of preferred shares and convertible notes but are not currently convertible or exercisable because of beneficial ownership limitations on conversion. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Biofrontera.
Biofrontera Inc. filed a current report to let investors know it has released a press release with preliminary, unaudited revenue figures for the fourth quarter and full year ended December 31, 2025. The press release, dated January 13, 2026, is included as Exhibit 99.1 and incorporated by reference.
The company notes that these revenue numbers are preliminary estimates and remain subject to its normal review processes, meaning the final fourth quarter results could differ materially. The disclosure is furnished rather than filed under the Exchange Act, limiting certain legal liabilities, and Biofrontera includes standard cautionary language that these forward‑looking statements reflect management’s views only as of the date of the report.
Biofrontera Inc. reported that it received a notice from Nasdaq stating its common stock is not in compliance with the Nasdaq Capital Market’s minimum bid price rule, which requires a closing bid of at least $1.00 per share. The stock’s closing bid was below $1.00 for 34 consecutive business days, triggering the deficiency notice.
The company has 180 calendar days, until June 30, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least 10 consecutive business days. If it fails to do so, Biofrontera may seek an additional compliance period, potentially including a reverse stock split, but its securities could ultimately face delisting if requirements are not met. The company plans to monitor its share price and consider available options, while noting there is no assurance it will regain or maintain compliance.